Clinical Trials Logo

Metastatic Leiomyosarcoma clinical trials

View clinical trials related to Metastatic Leiomyosarcoma.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03670069 Terminated - Clinical trials for Metastatic Soft Tissue Sarcoma

Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

Start date: September 30, 2019
Phase: Phase 1
Study type: Interventional

This pilot phase I trial studies how well itacitinib works in treating patients with sarcomas that do not respond to treatment (refractory) and have spread to other parts of the body (advanced/metastatic). Itacitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03074318 Terminated - Clinical trials for Metastatic Leiomyosarcoma

Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery

Start date: September 28, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II studies the side effects of avelumab and trabectedin and how well they work in treating patients with leiomyosarcoma or liposarcoma that has spread to other places in the body (metastatic) or cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as trabectedin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving avelumab and trabectedin may work better in treating patients with liposarcoma or leiomyosarcoma.

NCT ID: NCT02601209 Terminated - Myxofibrosarcoma Clinical Trials

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

Start date: November 30, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of sapanisertib and to see how well it works compared to pazopanib hydrochloride in treating patients with sarcoma that is too large to be removed (locally advanced) or has spread to other areas of the body (metastatic). Sapanisertib and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.